Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

EEGI, SVNT, JAZZ, PTEN - Weekend Stock Review

Eline Entertainment Group, Inc.’s (PINK SHEETS:EEGI) subsidiary Innovation Investment Group Inc. CEO Hong Wei attended a risk investor and decision-making course.

The course, named Risk Investor Decision-Making Flow, was instructed by IDGVC Partners, a China-focused investment firm with over US$2.5B capital under management. With an in-depth understanding of the local market, IDGVC invests in high quality companies with long-term growth potential and continuously dedicate themselves to the growth of great Chinese companies.

Ms. Hong Wei, a prominent motivational speaker in China and a firm believer in continuous education, attended the course in the morning and a service marketing conference in the afternoon, and was pleased with the course’s informative structure.

More about EEGI at:



Savient Pharmaceuticals, Inc. (Nasdaq:SVNT) announced on November 4, 2010 that it plans to commence shipments of KRYSTEXXA™ to specialty distributors on November 30, 2010. KRYSTEXXA, a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy, is then expected to be commercially available for prescription as of December 1, 2010. In conjunction with the commercial availability of KRYSTEXXA, Savient plans to launch its reimbursement and pharmacovigilance hotline services on November 22, 2010 for use by prescribers and patients. Savient expects to announce the pricing for KRYSTEXXA at the time it commences commercial distribution.
Savient Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing KRYSTEXXA, a biologic PEGylated uricase in the United States. The KRYSTEXXA is being developed as a treatment for chronic gout in patients refractory to conventional therapy.

Jazz Pharmaceuticals, Inc. (Nasdaq:JAZZ) Shares of Jazz Pharmaceuticals Inc. rose to a nine-year high Friday November 5, 2010, capping a weeklong rally after the company reported strong third-quarter results and raised its annual forecasts. Jazz said its sales improved after it raised the price of its narcolepsy drug Xyrem, which is expected to boost its sales for the rest of the year. Its shares advanced to their highest prices since early 2001.
Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes products for neurology and psychiatry primarily in the United States.

Patterson-UTI Energy Inc. (Nasdaq:PTEN) reported that for the month of October 2010, the Company had an average of 192 drilling rigs operating, including 180 rigs in the United States and 12 rigs in Canada.
Average drilling rigs operating reported in the Company’s monthly announcements represent the average number of the Company’s drilling rigs that were operating under a drilling contract. The Company cautioned that numerous factors in addition to average drilling rigs operating can impact the Company’s operating results and that a particular trend in the number of drilling rigs operating may or may not indicate a trend in or be indicative of the Company’s financial performance. The Company intends to continue providing monthly updates on drilling rigs operating shortly after the end of each month.
Patterson-UTI Energy, Inc. subsidiaries primarily provide onshore contract drilling and pressure pumping services to exploration and production companies in North America. Patterson-UTI Drilling Company LLC has approximately 350 marketable land-based drilling rigs that operate primarily in the oil and natural gas producing regions of Texas, New Mexico, Oklahoma, Arkansas, Louisiana, Mississippi, Colorado, Utah, Wyoming, Montana, North Dakota, Pennsylvania, West Virginia and western Canada. Universal Well Services, Inc., Universal Pressure Pumping, Inc. and Universal Wireline, Inc. provide well services primarily in Texas and the Appalachian region.


Sign-Up For Free Stock Alerts At



Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more at ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for Eline Entertainment Group, Inc. (OTCPK:EEGI).